CLINICAL TRIALS
Dermatology

CURRENT TRIALS

PREMIER DERMATOLOGY RESEARCH CENTER IN KANSAS

 

Kelly Liddy at 785-273-2788 ext. 137.

KMC Research Center, Dermatology Division

2921 SW Wanamaker Dr.

Topeka, KS 66614

CONTACT US

Success! Message received.

KMC DERMATOLOGY CURRENT CLINICAL TRIALS:

ATOPIC DERMATITIS

1. An open-label, single-arm study to assess the safety and efficacy of Lebrikizumab in adolescent patients with moderate-

    to-severe Atopic Dermatitis (AD). The primary objective of this study is to evaluate the safety and efficacy of Lebrikizumab

    in adolescent patients (≥ 12 to < 18 years weighing ≥ 40 kg) with moderate-to-severe AD.

       

Type of Study: Subcutaneous injection every four weeks (Chance of placebo).

Who: Age 12-18 years with moderate-to-severe Atopic Dermatitis (AD)

Duration: 68 weeks

Compensation: Yes

2. A phase 3, 16-week, randomized, double-blind, placebo-controlled, parallel-group study to assess the impact of Lebrikizumab on vaccine responses in adult patients with moderate-to-severe Atopic Dermatitis (AD).

Type of Study: Subcutaneous injection every two weeks (Chance of placebo). Subject will receive both Tdap and MCV vaccinations.

Who: Individuals 18-55 with moderate-to-severe Atopic Dermatitis (AD)

Duration: 32 weeks

Compensation: Yes

 

 

PRURIGO NODULARIS

1. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Nemolizumab in subjects

    with Prurigo Nodularis

Type of Study: Subcutaneous injection every four weeks (Chance of placebo)

Who: Individuals 18 years of age, or older with Prurigo Nodularis.

Duration: 36 weeks

Compensation: Yes

 

2. A prospective, multicenter, long-term study to assess the safety and efficacy of Nemolizumab in subjects with Prurigo

    NodularisThis study is only open to subjects who have participated in prior Nemolizumab PN phase 2a or phase 3

    studies.

Type of Study: Subcutaneous injection every four weeks (Chance of placebo)

Who: Individuals 18 years of age, or older with prurigo nodularis who have completed the prior Nemolizumab PN phase 2a or phase 3 studies.

Duration: 64 weeks

Compensation: Yes

 

PLAQUE PSORIASIS

1. A multicenter, randomized, parallel-group, double-blind, placebo-controlled (12-17 years) including a single open-label

    arm (6-11 years) study to evaluate the efficacy, safety, and pharmacokinetics of Certolizumab Pegol (CZP) in pediatric

    study participants with moderate to severe chronic Plaque Psoriasis (PSO).

Type of Study: Subcutaneous injection every two weeks (Chance of placebo) (subjects age 12-17) or open-label (subjects age 6-11).

Who: Individuals 6-17 with a diagnosis of moderate-to-severe Plaque Psoriasis (PSO)

Duration: 169 weeks

Compensation: Yes

2. A multicenter, randomized, double-blinded study evaluating the pharmacokinetics, efficacy, and safety of multiple

    switches between Ustekinumab and ABP 654 compared with continued use of Ustekinumab in subjects with moderate-to-

    severe Plaque Psoriasis (PSO).

Type of Study: Subcutaneous injection every four or more weeks (Chance of placebo)

Who: Individuals 18-75 with a diagnosis of moderate-to-severe Plaque Psoriasis (PSO)

Duration: 56 weeks

Compensation: Yes

UPCOMING TRIALS:

Atopic Dermatitis: Phase 3; adolescent & adult subjects on monotherapy with study drug; late 2021

Atopic Dermatitis: Phase 3; adolescent & adult subjects on study drug + topical corticosteroid; late 2021

Atopic Dermatitis: Phase 3; adolescent; rollover from above; late 2021

Interested in participating in or learning more about a Dermatology clinical trial? Please call Kelly Liddy at

785-273-2788 ext. 137.